Gabriel Martínez-Botella

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 225 citations

Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control

Alex M. Aronov, Qing Tang, Gabriel Martínez-Botella et al. · Journal of Medicinal Chemistry · 2009 · 144 citations · Full text

Drug Target, Chemical Biology, Tumor Biology +17

Flipped Out:  Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors

Alex M. Aronov, Christopher Baker, Guy W. Bemis et al. · Journal of Medicinal Chemistry · 2007 · 118 citations · Full text

Medicinal Chemistry, Drug Target, Medicine +12

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

Immunology, Immunologic Mechanism, Janus Tyrosine Kinases +16

Antibacterial Inhibitors of Gram-Positive Thymidylate Kinase: Structure–Activity Relationships and Chiral Preference of a New Hydrophobic Binding Region

Sameer Kawatkar, Thomas A. Keating, N.B. Olivier et al. · Journal of Medicinal Chemistry · 2014 · 61 citations

Antibiotic Adjuvant, Molecular Biology, Peptide Science +23